Conversely, a separate group subsequently reported a direct correlation between ARID1A expression and ANXA1 expression, and that although ANXA1-positive HER2+ BC tumors exhibited a mortality rate three times higher than that of ANXA1-negative tumors, ANXA1 activity has no prognostic importance in determining trastuzumab resistance [140]. The gene discussed is ERBB2; the disease is breast cancer.